Biologicals

Yellow Fever

Requirements for yellow fever vaccine, Annex 2

(Requirements for Biological Substances, No. 3, revised 1995) WHO Technical Report Series, No. 872, 1998

Proposed amendments to the Requirements for Yellow Fever Vaccines (Requirements for Biological Substances No. 3, Annex 2) WHO Technical Report Series No. 872

ESSENTIAL MEDICINES AND HEALTH PRODUCTS



UPCOMING EVENTS


  • WHO working group meeting on RSV vaccine standardization and clinical evaluation, Geneva, Switzerland, 3-5 February 2016
  • TCV Workshop, NIBSC, Potters Bar, UK, 8-10 March 2016
  • WHO informal consultation on labelling information on influenza vaccines intended to be used for pregnant women, Geneva, Switzerland, 4-5 April 2016
  • WHO informal consultation on WHO guidelines on regulatory preparedness for vaccine non-producing countries in response to pandemic influenza emergency, Geneva, Switzerland, 6-7 April 2016
  • WHO working group meeting on guidelines on the quality, safety and efficacy of Ebola vaccines, Geneva, Switzerland, 4-5 May 2016

Contacts


Technologies Standards and Norms (TSN)
Essential Medicines and Health Products (EMP)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971